Log in to your Inderes Free account to see all free content on this page.
Ascelia Pharma
3.00 SEK
+2.04 %
Less than 1K followers
ACE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Ascelia Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -36.8 | -93.4 | -137.9 | -147.0 | -110.9 | -67.8 | -74.4 |
| EBIT | -36.8 | -93.4 | -137.9 | -147.0 | -110.9 | -67.8 | -74.4 |
| Profit before taxes | -81.5 | -99.7 | -129.5 | -133.2 | -109.6 | -80.1 | -76.7 |
| Net income | -40.0 | -98.7 | -125.9 | -131.2 | -109.3 | -80.0 | -76.3 |
| EPS | -1.19 | -2.38 | -2.58 | -2.61 | -2.24 | -1.48 | -0.67 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -16.9 % | -41.8 % | -40.9 % | -72.6 % | -147.0 % | -101.4 % | -76.7 % |
| ROI | -16.0 % | -38.6 % | -37.8 % | -60.0 % | -125.5 % | -56.8 % | -68.1 % |
Login required
This content is only available for logged in users